US6673602B1
(en)
|
1999-06-11 |
2004-01-06 |
The General Hospital Corporation |
Herpes simplex virus amplicon vector targeting system and method of using same
|
EP1444353A2
(en)
*
|
1999-06-11 |
2004-08-11 |
The General Hospital Corporation |
Herpes simplex virus amplicon vector targeting system and method of using same
|
GB0203285D0
(en)
*
|
2002-02-12 |
2002-03-27 |
Brown Susanne M |
An herpes simplex virus complex
|
US7550148B2
(en)
*
|
2002-10-07 |
2009-06-23 |
The University Of Chicago |
Targeting of Herpes simplex virus to specific receptors
|
ES2741523T3
(en)
*
|
2002-10-07 |
2020-02-11 |
Univ Chicago |
Direction of the herpes simplex virus to specific receptors
|
US8927251B2
(en)
|
2002-10-07 |
2015-01-06 |
The University Of Chicago |
Targeting of herpes simplex virus to specific receptors
|
US20040166091A1
(en)
|
2003-02-24 |
2004-08-26 |
Genvec, Inc. |
Materials and methods for treating disorders of the ear
|
GB0317511D0
(en)
*
|
2003-07-25 |
2003-08-27 |
Biovex Ltd |
Viral vectors
|
JP2008518599A
(en)
|
2004-10-28 |
2008-06-05 |
ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション |
Peripheral delivery glutamate decarboxylase gene therapy for spinal cord injury pain
|
WO2006132925A2
(en)
|
2005-06-01 |
2006-12-14 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
|
WO2008143875A1
(en)
|
2007-05-14 |
2008-11-27 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Targeted delivery of glycine receptors to excitable cells
|
US20120219583A1
(en)
|
2009-10-16 |
2012-08-30 |
Los Alamos National Security, Llc |
Nucleic acid sequences encoding expandable hiv mosaic proteins
|
AU2011232435B2
(en)
|
2010-03-23 |
2016-01-28 |
Intrexon Corporation |
Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
|
WO2011130749A2
(en)
|
2010-04-16 |
2011-10-20 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
|
AU2012225749B2
(en)
|
2011-03-04 |
2015-01-22 |
Intrexon Corporation |
Vectors conditionally expressing protein
|
CN113278653A
(en)
|
2013-07-17 |
2021-08-20 |
匹兹堡大学-属高等教育联邦体系 |
Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production
|
WO2015066042A1
(en)
|
2013-10-28 |
2015-05-07 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Oncolytic hsv vector
|
US9580699B2
(en)
|
2014-04-17 |
2017-02-28 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
TRPV1 modulatory gene product that affects TRPV1-specific pain behavioral responses identified in a functional screen of an HSV-based cDNA library
|
CA2957802A1
(en)
|
2014-09-07 |
2016-03-10 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
|
TWI710635B
(en)
|
2014-10-09 |
2020-11-21 |
美商珍維克公司 |
Adenoviral vector encoding human atonal homolog-1 (hath1)
|
CN116904404A
(en)
|
2016-01-27 |
2023-10-20 |
昂克诺斯公司 |
Oncolytic viral vectors and uses thereof
|
US11007236B2
(en)
*
|
2016-06-09 |
2021-05-18 |
Alma Mater Studiorum Universita Di Bologna |
Herpesvirus with modified glycoprotein B
|
WO2018006005A1
(en)
|
2016-06-30 |
2018-01-04 |
Oncorus, Inc. |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
EP3500696A4
(en)
|
2016-08-16 |
2020-04-08 |
Bluebird Bio, Inc. |
Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use
|
CA3034782A1
(en)
|
2016-08-23 |
2018-03-01 |
Bluebird Bio, Inc. |
Tim3 homing endonuclease variants, compositions, and methods of use
|
IL265045B2
(en)
|
2016-09-08 |
2023-09-01 |
Bluebird Bio Inc |
Pd-1 homing endonuclease variants, compositions, and methods of use
|
CN110050066A
(en)
|
2016-10-17 |
2019-07-23 |
蓝鸟生物公司 |
TGF β R2 endonuclease variants, composition and application method
|
CN110072885B
(en)
|
2016-11-17 |
2023-12-19 |
2赛文缇生物公司 |
TGF beta signal converter
|
EP3565572A1
(en)
|
2017-01-07 |
2019-11-13 |
Selecta Biosciences, Inc. |
Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
|
EP4317447A3
(en)
|
2017-02-15 |
2024-05-01 |
2seventy bio, Inc. |
Donor repair templates multiplex genome editing
|
KR20190135017A
(en)
|
2017-03-30 |
2019-12-05 |
더 유니버서티 어브 퀸슬랜드 |
Chimeric Molecules and Their Uses
|
KR20230147767A
(en)
|
2017-05-25 |
2023-10-23 |
2세븐티 바이오, 인코포레이티드 |
Cblb endonuclease variants, compositions, and methods of use
|
JP7249323B2
(en)
|
2017-07-26 |
2023-03-30 |
オンコラス, インコーポレイテッド |
Oncolytic virus vector and use thereof
|
WO2019070974A1
(en)
|
2017-10-04 |
2019-04-11 |
Bluebird Bio, Inc. |
Pcsk9 endonuclease variants, compositions, and methods of use
|
EP3694543A1
(en)
|
2017-10-13 |
2020-08-19 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
EP3731850A4
(en)
|
2017-12-29 |
2021-12-01 |
Oncorus, Inc. |
Oncolytic viral delivery of therapeutic polypeptides
|
JP2021515037A
(en)
|
2018-02-26 |
2021-06-17 |
アントルクス,インコーポレーテッド |
Tolerant liposomes and how to use them
|
US20210261659A1
(en)
|
2018-06-14 |
2021-08-26 |
Bluebird Bio, Inc. |
Cd79a chimeric antigen receptors
|
WO2020072059A1
(en)
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
KR20220004121A
(en)
|
2019-04-28 |
2022-01-11 |
셀렉타 바이오사이언시즈, 인크. |
Methods of treating a subject with pre-existing immunity to a viral transfer vector
|
AU2020284555A1
(en)
|
2019-05-28 |
2021-12-23 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuated anti-viral transfer vector immune response
|
CN114765990A
(en)
|
2019-10-10 |
2022-07-19 |
昂克诺斯公司 |
Dual viruses and dual oncolytic viruses and methods of treatment
|
CN115667289A
(en)
|
2020-04-10 |
2023-01-31 |
索拉生物科学有限公司 |
Compositions and methods for treating protein aggregation disorders
|
AU2021265088A1
(en)
|
2020-04-28 |
2022-11-03 |
Sola Biosciences Llc |
Compositions and methods for the treatment of TDP-43 proteinopathies
|
JP2023529371A
(en)
|
2020-06-05 |
2023-07-10 |
ソラ・バイオサイエンシズ・エルエルシー |
Compositions and methods for the treatment of synucleinopathies
|
KR20230042263A
(en)
|
2020-06-09 |
2023-03-28 |
이노자임 파마, 인코포레이티드 |
Soluble ENPP1 or ENPP3 Proteins and Uses Thereof
|
AU2021367952A1
(en)
|
2020-10-26 |
2023-06-08 |
Sola Biosciences Llc |
Compositions and methods for the treatment of alzheimer's disease
|
KR20240034234A
(en)
|
2021-07-14 |
2024-03-13 |
2세븐티 바이오, 인코포레이티드 |
Engineered T cell receptor fused to binding domain from antibody
|
WO2023060221A2
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of proteopathies
|
CA3234720A1
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of p53-mediated cancers
|
US20230141563A1
(en)
|
2021-10-12 |
2023-05-11 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
US20230357437A1
(en)
|
2022-03-09 |
2023-11-09 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
WO2023196996A2
(en)
|
2022-04-08 |
2023-10-12 |
2Seventy Bio, Inc. |
Multipartite receptor and signaling complexes
|